These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8285546)

  • 1. Comparison of the cost-effectiveness of administering heparin subcutaneously or intravenously for the treatment of deep vein thrombosis.
    Barber ND; Hoffmeyer UK
    Ann R Coll Surg Engl; 1993 Nov; 75(6):430-3. PubMed ID: 8285546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
    Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
    CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.
    Simonneau G; Charbonnier B; Decousus H; Planchon B; Ninet J; Sie P; Silsiguen M; Combe S
    Arch Intern Med; 1993 Jul; 153(13):1541-6. PubMed ID: 8391792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of hospital cost of six days of treatment of deep venous thrombosis. Comparison of subcutaneous nadroparin and intravenous heparin in 40 patients].
    Lévesque H; Cailleux N; Vasse D; Legallicier B; Moore N; Borg JY; Hantute N; Thuillez C; Courtois H
    Therapie; 1994; 49(2):101-5. PubMed ID: 7817331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis.
    Stricker H; Marchetti O; Haeberli A; Mombelli G
    Thromb Haemost; 1999 Oct; 82(4):1227-31. PubMed ID: 10544903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Heparin in deep venous thrombosis of the leg--effectiveness and safety].
    Gatterer E; Stöllberger C; Slany J; Stöberl C; Jaksch J
    Wien Klin Wochenschr; 1988 Sep; 100(18):601-5. PubMed ID: 3188535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective.
    Hull RD; Raskob GE; Rosenbloom D; Pineo GF; Lerner RG; Gafni A; Trowbridge AA; Elliott CG; Green D; Feinglass J
    Arch Intern Med; 1997 Feb; 157(3):289-94. PubMed ID: 9040295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Heparin treatment. Comparison between intravenous and subcutaneous administration].
    Krähenbühl B; Simon CA; Bouvier CA; Schinas P; Hopf MA; Cochet B
    Schweiz Med Wochenschr; 1979 Sep; 109(36):1322-5. PubMed ID: 504973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Subcutaneous injections and intravenous infusion of sodium salt of heparin in the treatment of thrombosis of deep veins of the lower extremities].
    Lopaciuk S; Misiak A; Wisławski S; Ciesielski L; Korzycki J; Judkiewicz L; Lewandowski K; Tokarz A; Kłoczko J; Bielawiec M
    Pol Tyg Lek; 1990 Nov 19-26; 45(47-48):949-52. PubMed ID: 2104438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of deep vein thrombosis with continuous intravenous infusion of LMWH in children--an alternative to subcutaneous application when needed.
    Blatný J; Fiamoli V
    Vnitr Lek; 2009 Mar; 55(3):227-32. PubMed ID: 19378852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
    Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
    Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness and ease of administration of low molecular weight heparin in deep vein thrombosis.
    Teo CP; Lim HL; Kueh YK
    Thromb Haemost; 1994 Aug; 72(2):328-9. PubMed ID: 7831676
    [No Abstract]   [Full Text] [Related]  

  • 13. [Health care economics evaluation of inpatient treatment of venous thrombosis with unfractionated heparin versus subcutaneous low molecular weight heparin at home].
    Osterkorn D; Schramm W; Szucs T
    Med Klin (Munich); 1996 Sep; 91(9):607-9. PubMed ID: 8984321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of the use of nadroparin in the treatment of deep-vein thrombosis in Switzerland.
    Lloyd AC; Aitken JA; Hoffmeyer UK; Kelso EJ; Wakerly EC; Barber ND
    Ann Pharmacother; 1997; 31(7-8):842-6. PubMed ID: 9220041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis--an economic evaluation. TASMAN Study Group.
    van den Belt AG; Bossuyt PM; Prins MH; Gallus AS; Büller HR
    Thromb Haemost; 1998 Feb; 79(2):259-63. PubMed ID: 9493572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
    Boneu B; Navarro C; Cambus JP; Caplain H; d'Azemar P; Necciari J; Duret JP; Gaud C; Sié P
    Thromb Haemost; 1998 Feb; 79(2):338-41. PubMed ID: 9493587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group.
    Charbonnier BA; Fiessinger JN; Banga JD; Wenzel E; d'Azemar P; Sagnard L
    Thromb Haemost; 1998 May; 79(5):897-901. PubMed ID: 9609216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.
    McGarry LJ; Thompson D; Weinstein MC; Goldhaber SZ
    Am J Manag Care; 2004 Sep; 10(9):632-42. PubMed ID: 15515996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy of thrombosis with conventional heparin].
    Harenberg J
    Z Kardiol; 1993; 82 Suppl 2():71-5. PubMed ID: 8328212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous compared with intravenous heparin for deep vein thrombosis.
    Burnum JF
    Ann Intern Med; 1992 Aug; 117(3):265; author reply 265-6. PubMed ID: 1616224
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.